Foresight Diagnostic & Allogene Therapeutics Extend Collaboration to Develop Minimal Residual Disease (MRD) Assay
Shots:
- Foresight & Allogene have expanded their strategic collaboration to develop minimal residual disease (MRD) assay as companion diagnostic to identify candidates for Allogene's ALPHA3 trial assessing cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL) pts
- As per the collaboration, Allogene & Foresight will develop Foresight's MRD assay in the EU, UK, Canada & Australia to support cema-cel's clinical development. Collaboration incl. investment for further MRD assay development, clinical sample testing & milestone payments
- Cema-cel is being evaluated in pivotal ALPHA3 trial as a 1L treatment for LBCL, where MRD+ pts in remission identified via Foresight's CLARITY IUO assay may receive single cema-cel dose to prevent disease recurrence
Ref: Foresight Diagnostic | Image: Foresight Diagnostic & Allogene Therapeutics
Related News:- Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
